697754-57-7

Upstream product

• 618056-39-6 3-(4-benzyloxy-5-methoxy-2-{[3,4-dimethoxyphenyl]carbonyl} phenyl)pentan-2-one 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 618056-38-5 3-(3-methoxy-4-benzyloxyphenyl)pentan-2-ol 

Downstream Products

• 95500-09-7 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE 

Relevant academic research and scientific papers

Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammels.

Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: 1wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4,

Method of lowering body temperature with (R) - 2,3-benzodiazepines

An (R)-2,3-benzodiazepine of Formula I, substantially isolated from the corresponding (S)-enantiomer thereof, is administered to lower the body temperature of an individual.

Method of lowering body temperature with (S)-2,3-benzodiazepines

An (S)-2,3-benzodiazepine of Formula I, substantially isolated from the corresponding (R)-enantiomer thereof, is administered to lower the body temperature of an individual.

Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and wherein the compound comprises the (S)-enantiomer, administered for modulation of dopamine responses and treatment of dopamine-mediated disorders.

Method of increasing neutrophil production using 2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammals.

Treatment of inflammatory disorders with 2,3- benzodiazepines

Compounds according to formula I: 1 wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders, particularly inflammatory disorders mediated by LTB4,

Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines

Compounds according to formula I: are disclosed wherein R1, R2, R3, R4, R5and R6as defined herein, are administered for irritable bowel syndrome and nonulcer dyspepsia.